Abstract: Published studies reported that loss of function of the p15 INK4B gene is caused by hypermethylation; however, whether or not the inactivation is associated with the incidence and clinical significance of multiple myeloma (MM) remains unclear. In this study, we performed a meta-analysis to quantitatively determine the effects of p15 hypermethylation on the incidence of MM. The related research articles in English and Chinese languages were evaluated. The data were extracted and assessed independently. The pooled data were analyzed and odds ratios were calculated and summarized. Sixteen eligible studies were selected for final analysis. We demonstrated that p15 hypermethylation is significantly higher in MM than that in normal bone marrow, as well as monoclonal gammopathy of undetermined significance. However, aberrant p15 hypermethylation was not significantly higher in advanced MM than that in early-stage MM. The results of this study reveal that p15 hypermethylation is correlated with an increased risk in the progression of monoclonal gammopathy of undetermined significance to MM. p15 hypermethylation, which induces the loss of function of the p15 gene, plays a critical role in the early tumorigenesis of MM and serves as a reputable diagnostic marker and potential drug target.
Introduction
Multiple myeloma (MM) is a clonal malignancy characterized by the production of monoclonal immunoglobulin and the proliferation of malignant plasma cells in the bone marrow. 1 Clinically, MM starts with immortalization of a post-germinal center B cell and presents as asymptomatic monoclonal gammopathy of undetermined significance (MGUS). MGUS plasma cells share many abnormal characteristics with MM plasma cells. MGUS is considered as the precursor of MM, since it is able to progress to symptomatic MM at a rate of 1% per year. 2 Over the years, newly approved drugs such as bortezomib, lenalidomide, and thalidomide have shown significant benefits in heavily pretreated MM patients. [3] [4] [5] [6] However, the majority of MM patients still relapse; therefore, the identification of biomarker and potential drug target is still necessary to improve the survival rate in the patients who are refractory to chemotherapy. Epigenetic alteration, particularly aberrant DNA methylation, is one of the best-characterized epigenetic modifications contributing to tumor initiation, progression, and prognosis.
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Wei et al including MM. [10] [11] [12] The p15, as a tumor suppression gene, is hypermethylated in many tumors including MM. p15 INK4b (p15), one of the INK4 members, is a cyclindependent kinase inhibitor. 13, 14 Previously, p15 INK4b , as well as other INK4 members, p14 ARF , p16 INK4a , p21 CIP1 , and p27 KIP2 , have been revealed to be involved in the neoplastic process of carcinomas. 15, 16 Although a number of reports have determined that the inactivation of p15 gene is mainly induced by hypermethylation in MM, the reported rates of p15 hypermethylation in MM are remarkably diverse. In addition, whether or not the inactivation of p15 gene is associated with the incidence and clinical significance of MM has not been thoroughly determined. Hence, we performed a systematic review and meta-analysis to determine the effects of p15 hypermethylation on the incidence and clinical significance of MM.
Methods
search strategy and selection criteria
We identified studies from Embase, ISI web, and PubMed from August 1, 1995 to July, 2015 using the following search terms: "multiple myeloma", "Kahler's disease", "plasma cell myeloma", "methylation", "p15", "p15 INK4B ", and "cyclindependent kinase inhibitor 2B". We also manually searched reviews for additional related articles and the reference lists of the retrieved articles. We only took into account the studies published in the English and Chinese languages for full-text reading and final evaluations. After the exclusion of redundant and/or nonrelevant publications from different databases, the remaining articles were analyzed and evaluated in the full-text version for inclusion and exclusion criteria.
To be eligible, a study needed to meet the following criteria: 1) p15 methylation evaluated in primary MM; 2) p15 methylation determined by polymerase chain reaction (PCR); 3) research revealed the relationship between p15 methylation of MM clinicopathological parameters and prognosis; and 4) studies provided sufficient data and information to determine odds ratio (OR). The exclusion criteria included: 1) case reports, conference abstracts, letters, reviews, editorials, and expert opinion; and 2) all publications regarding in vitro/ ex vivo studies, cell lines, and human xenografts. In addition to inclusion criteria, "aberrant" p15 methylation or p15 hypermethylation is defined by clear PCR product band detected by methylation-specific polymerase chain reaction (MSP).
Data extraction and methodological assessment
Two authors (BW, SY) independently reviewed and extracted data from eligible studies. Two authors (BZ, YF) reviewed all the articles that fit the inclusion and exclusion criteria. Disagreements were resolved through discussion and consensus. For each study, the following information was recorded: year of publication, the first author name, number of cases, sample source, methylation detection method, clinicopathological parameters, methylation rate, and follow-up results. Heterogeneity of investigations was evaluated to determine whether or not the data of the various studies could be analyzed.
Three investigators (BW, SY, and BZ) read through each publication independently for the methodological evaluation of the studies, and assessed and scored them according to the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines and European Lung Cancer Working Party (ELCWP) quality scale. 17, 18 They provided the quality scores and reached a consensus value for each item.
statistical analysis
The Review Manager 5.2 (Cochrane Collaboration, Oxford, UK) and STATA 12.0 (StataCorp LP, College Station, TX, USA) were selected for analysis. The frequency of p15 promoter hypermethylation was compared in different tumor characteristics. The pooled frequency of p15 promoter hypermethylation and 95% confidence intervals (CIs) were estimated. Cochran's Q test 19 and the I 2 statistic were used for evaluating heterogeneity among studies. 20, 21 A fixed-effect model was used to calculate parameters when heterogeneity was not an issue (I 2 values ,50%). A random-effects model was used to pool data and attempt to identify potential sources of heterogeneity based on subgroup analyses, if there was substantial heterogeneity (I 2 values $50%). P-values tailed less than 0.05 were considered statistically significant.
The method reported by Egger et al was used for assessing publication bias. 22 Meta-regression, subgroup analysis, and sensitivity analysis were used for exploring reasons of statistical heterogeneity. STATA version 10.0 was used for the analysis of meta-regression and publication bias.
Results
Sixteen studies published from 1997 to 2014 were included in the meta-analysis, as shown in Figure 1 . A total of 607 patients from Argentina, Brazil, the People's Republic of China, Hong Kong, France, Spain, Austria, and USA were enrolled; Table 1 showed their basic characteristics.
The meta-analysis showed that P15 hypermethylation is significantly higher in MM than that in normal bone marrow samples. 
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Wei et al indicates that p15 inactivation through hypermethylation plays an important role in the pathogenesis of MM. We further determined that p15 hypermethylation also occurs in MGUS, which is significantly less than that in MM (OR=2.25, 95% CI=1.20-4.21, P=0.01); the pooled frequency rate of the p15 hypermethylation in MM is 26.7% whereas in MGUS it is 13.9%, as shown in Figure 3A , but higher than that in normal bone marrow (OR=5.40, 95% CI=1.09-26.86, P=0.04), as shown in Figure 3B . We analyzed 179 MM patients pooled in five studies to assess whether or not the aberrant p15 hypermethylation in MM was associated with advanced stages of MM. As shown in Figure 4 , aberrant p15 hypermethylation is not significantly higher in advanced MM (Stage III) than that in early-stage MM (Stage I and II) (OR=1.17, 95% CI=0.54-2.54, P=0.69). Staging of MM is the process of finding out the amount of malignant myeloma cells that have advanced; it relies mainly on levels of albumin and beta-2-microglobulin in the blood, platelet count, kidney function, and patient's age. 23, 24 MM stages which are equivalent to progression are determined by evolving mutations and epigenetic mechanisms. Our results suggest that the inactivation of p15 gene expression by promoter hypermethylation may not play an important role in MM progression.
Finally, we performed sensitivity analyses, in which one study at a time was removed, to assess the result stability. The pooled ORs were not significantly changed, indicating the stability of our analyses. The funnel plots are largely symmetric ( Figure 5 ), suggesting there were no publication biases in the meta-analysis of p15 hypermethylation and clinicopathological features.
Discussion
The p15 gene, along with p14 and p16, is the most prevalent hypermethylated cell cycle regulatory gene in tumorigenesis and progression of MM. [25] [26] [27] [28] [29] We conducted this meta-analysis to determine the correlation between p15 hypermethylation and MM. Analysis of the pooled data showed that 1) significantly higher p15 hypermethylation was detected in MM than that in normal bone marrow; 2) p15 hypermethylation was also detected in MGUS, but significantly less than that in MM; 3) p15 hypermethylation was also higher in MGUS than that in normal bone marrow; and 4) p15 hypermethylation was not significantly higher in advanced MM than that in early-stage MM. Epigenetic changes contribute to tumorigenesis and affect initial steps in malignant transformation by altering genome stability and regulating gene expression. 30 MM develops as a result of multistep tumorigenic events, in which approximately one-third of all MM cases have a history of preceding MGUS or smoldering myeloma. Recent data also show that MM is consistently preceded by a precursor state, MGUS. [31] [32] [33] MGUS, a premalignant and early stage of myeloma, was characterized by striking, widespread hypomethylation while gene-specific hypermethylation was found to occur in the advanced stages of myeloma. 30 We noticed that Wang et al 27 have performed a meta-analysis on p15 and p16 genes in MM; however, the role of p15 hypermethylation in different
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Wei et al stages of MM was not elucidated. The results from the current study demonstrates that the hypermethylation rate of p15 gene promoter in MGUS was higher than that in normal bone marrow, indicating that p15 promoter hypermethylation was an early event in myelomagenesis. We did not find that p15 hypermethylation in MM was associated with advanced stage. These results also indicate that p15 hypermethylation could potentially be an early event. The results that significantly higher p15 hypermethylation was detected in MM than that in normal bone marrow and MGUS indicate that p15 hypermethylation is common in MM. Since changes in p15 hypermethylation are reversible, drug treatment through demethylation may be useful to delay carcinogenesis and progression. This approach may bring new direction and hope for MM treatment through gene-targeted therapy.
Progression from MGUS to MM appears to mirror the accumulation of genetic abnormalities, suggesting a stepwise progression of genetic and epigenetic changes. 34 Hypermethylation of several tumor suppressors, such as p15, ARF, SOCS-1, p27 KIP1, RASSF1A, non-receptor type 6 (SHP1), death-associated protein kinase, and TP73 genes was reported in MGUS. 35, 36 Our meta-analysis showed that p15 gene hypermethylation in MGUS is higher than that in normal cohort. Our results also showed that p15 hypermethylation in MGUS was significantly less than that in MM. Therefore, hypermethylation of the p15 gene could potentially be involved in the progression of MGUS to MM. In addition, combining p15 with other tumor suppressor genes to develop several gene markers will be a valuable strategy for risk stratification to predict initial carcinogenesis and neoplastic progression of MM.
Limitations
This study has several potential limitations. First, the search strategy was restricted to articles published in English and Chinese. Articles with potentially high-quality data that were published in other languages were not included because of anticipated difficulties in obtaining accurate medical OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
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Clinicopathological significance of p15 promoter hypermethylation in MM translation. Second, the possibility of information and selection biases as well as unidentified confounders could not be completely excluded because all of the included studies were observational. Hence, caution should be taken when our findings are interpreted among the general populations. In addition, for MSP detection, it is usually to detect CpG island regions in the gene promoter or the first exon. The different location of detection sites may affect the methylation rate.
Conclusion
We performed a meta-analysis of 16 eligible studies. Our results demonstrated that p15 hypermethylation is significantly higher in MM than that in normal bone marrow, as well as in MGUS. However, aberrant p15 hypermethylation was not significantly higher in advanced MM than that in early-stage MM. The results of this meta-analysis suggest that p15 hypermethylation is associated with an increased risk in the progression of MGUS to MM. p15 hypermethylation, which induces the inactivation of p15 gene, plays an important role in the early tumorigenesis of MM and serves as a reputable prognostic marker and potential drug target.
Disclosure
The authors report no conflicts of interest in this work.
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. 
